Advocating for population health: The role of public health practitioners in the age of artificial intelligence.

Over the past decade, artificial intelligence (AI) has begun to transform Canadian organizations, driven by the promise of improved efficiency, better decision-making, and enhanced client experience. While AI holds great opportunities, there are also near-term impacts on the determinants of health and population health equity that are already emerging. If adoption is unregulated, there is a substantial risk that health inequities could be exacerbated through intended or unintended biases embedded in AI systems. New economic opportunities could be disproportionately leveraged by already privileged workers and owners of AI systems, reinforcing prevailing power dynamics. AI could also detrimentally affect population well-being by replacing human interactions rather than fostering social connectedness. Furthermore, AI-powered health misinformation could undermine effective public health communication. To respond to these challenges, public health must assess and report on the health equity impacts of AI, inform implementation to reduce health inequities, and facilitate intersectoral partnerships to foster development of policies and regulatory frameworks to mitigate risks. This commentary highlights AI's near-term risks for population health to inform a public health response.

RéSUMé: Au cours de la dernière décennie, l'intelligence artificielle (IA) a commencé à transformer les organismes canadiens en leur promettant une plus grande efficience, de meilleurs processus décisionnels et une expérience client enrichie. Bien qu'elle recèle d'immenses possibilités, l'IA aura des effets à court terme ­ qui se font d'ailleurs déjà sentir ­ sur les déterminants de la santé et sur l'équité en santé des populations. Si son adoption n'est pas réglementée, il se peut très bien que les iniquités en santé continuent d'être exacerbées par les préjugés, intentionnels ou non, ancrés dans les systèmes d'IA. Les nouvelles possibilités économiques pourraient être démesurément exploitées par les travailleurs et les travailleuses déjà privilégiés et par les propriétaires des systèmes d'IA, renforçant ainsi la dynamique de pouvoir existante. L'IA pourrait aussi nuire au bien-être des populations en remplaçant les interactions humaines au lieu de favoriser la connexité sociale. De plus, la mésinformation sur la santé alimentée par l'IA pourrait réduire l'efficacité des messages de santé publique. Pour relever ces défis, la santé publique devra évaluer et communiquer les effets de l'IA sur l'équité en santé, en modérer la mise en œuvre pour réduire les iniquités en santé, et faciliter des partenariats intersectoriels pour éclairer l'élaboration de politiques et de cadres réglementaires d'atténuation des risques. Le présent commentaire fait ressortir les risques à court terme de l'IA pour la santé des populations afin d'éclairer la riposte de la santé publique.

National burden of rheumatoid arthritis in Canada, 1990-2019: findings from the Global Burden of Disease Study 2019 - a GBD collaborator-led study.

OBJECTIVE: The objectives of this study were: (1) to describe burden of rheumatoid arthritis (RA) and trends from 1990 to 2019 using the Global Burden of Diseases, Injuries and Risk Factors Study (GBD) data, (2) to describe age and sex differences in RA and (3) to compare Canada's RA burden to that of other countries. METHODS: Disease burden indicators included prevalence, mortality, years of life lost (YLLs), years lived with disability (YLDs) and disability-adjusted life-years (DALYs). GBD estimated fatal and non-fatal outcomes using published literature, survey data and health insurance claims. Data were analysed by Bayesian meta-regression, cause of death ensemble model and other statistical methods. DALYs for Canada were compared with DALYs of countries with similarly high Socio-Demographic Index values. RESULTS: In Canada, the RA prevalence rate increased by 27% between 1990 and 2019, mortality rate decreased by 27%, YLL rate decreased by 30%, YLD increased by 27% and DALY rate increased by 13%, all age standardised. The decline in RA mortality and YLL rates was especially pronounced after 2002. The disease burden was higher in females for all indicators, and DALY rates were higher among older age groups, peaking at age 75-79 years. Prevalence and DALYs were higher in Canada compared with global rates. CONCLUSION: Trends in RA burden indicators over time and differences by age and sex have important implications for Canadian policy-makers, researchers and care providers. Early identification and management of RA in women may help reduce the overall burden of RA in Canada.

Developmental evaluation during the COVID-19 pandemic: Practice-based learnings from projects in British Columbia, Canada.

In this article, we explore experiences and learnings from adapting to challenges encountered in implementing three Developmental Evaluations (DE) in British Columbia, Canada within the evolving context of the COVID-19 pandemic. We situate our DE projects within our approach to the DE life cycle and describe challenges encountered and required adaptations in each phase of the life cycle. Regarding foundational aspects of DEs, we experienced challenges with relationship building, assessing and responding to the context, and ensuring continuous learning. These challenges were related to suboptimal embeddedness of the evaluators within the evaluated projects. We adapted by leveraging online channels to maintain communications and securing stakeholder engagement by assuming non-traditional DE roles based on our knowledge of the context to support project goals. Additional challenges experienced with mapping the rationale and goals of the projects, identifying domains for assessment, collecting data, making sense of the data and intervening were adapted to by facilitating online workshops, collecting data online and through proxy evaluators, while sharing methodological insights within the evaluation team. During evolving crises, like the COVID-19 pandemic, evaluators must embrace flexibility, leverage, and apply their knowledge of the evaluation context, lean on their strengths, purposefully reflect and share knowledge to optimise their DEs.

Defining the role of digital public health in the evolving digital health landscape: policy and practice implications in Canada. / Définition du rôle de la santé publique numérique dans le paysage changeant de la santé numérique : répercussions sur les politiques et les pratiques au Canada.

In this article, we argue that current digital health strategies across Canada do not appropriately consider the implications of digital technologies (DTs) for public health functions because they adopt a primarily clinical focus. We highlight differences between clinical medicine and public health, suggesting that conceptualizing digital public health (DPH) as a field distinct from, but related to, digital health is essential for the development of DTs in public health. Focussing on DPH may allow for DTs that deeply consider fundamental public health principles of health equity, social justice and action on the social and ecological determinants of health. Moreover, the digital transformation of health services catalyzed by the COVID-19 pandemic and changing public expectations about the speed and convenience of public health services necessitate a specific DPH focus. This imperative is reinforced by the need to address the growing role of DTs as determinants of health that influence health behaviours and outcomes. Making the distinction between DPH and digital health will require more specific DPH strategies that are aligned with emergent digital strategies across Canada, development of intersectoral transdisciplinary partnerships and updated competencies of the public health workforce to ensure that DTs in public health can improve health outcomes for all Canadians.

Dans cet article, nous soutenons que les stratégies actuelles en matière de santé numérique à l'échelle du Canada ne tiennent pas adéquatement compte des répercussions des technologies numériques sur les fonctions de santé publique, car elles ont une orientation principalement clinique. Nous soulignons les différences entre médecine clinique et santé publique et nous suggérons qu'il est essentiel, pour le développement des technologies numériques dans le domaine de la santé publique, de concevoir la santé publique numérique comme un domaine distinct de la santé numérique tout en étant lié à celle-ci. Si l'accent était mis sur la santé publique numérique, les technologies numériques pourraient tenir compte en profondeur des principes fondamentaux de la santé publique que sont l'équité en santé, la justice sociale et l'action sur les déterminants sociaux et environnementaux de la santé. De plus, la transformation numérique des services de santé, catalysée par la pandémie de COVID-19, et l'évolution des attentes du public à l'égard de la rapidité et de la commodité des services de santé publique exigent que l'on mette l'accent sur la santé publique numérique. Cet impératif est renforcé par la nécessité de prendre en compte le rôle croissant des technologies numériques en tant que déterminants de la santé ayant une influence sur les comportements et les résultats en matière de santé.